Compare CDRE & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRE | ALVO |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2021 | 2021 |
| Metric | CDRE | ALVO |
|---|---|---|
| Price | $34.16 | $4.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $39.67 | $8.00 |
| AVG Volume (30 Days) | 398.7K | ★ 828.9K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ 13.33 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $610,308,000.00 | N/A |
| Revenue This Year | $23.72 | $13.28 |
| Revenue Next Year | $6.89 | $18.63 |
| P/E Ratio | $109.35 | ★ $18.20 |
| Revenue Growth | ★ 7.53 | N/A |
| 52 Week Low | $25.73 | $2.94 |
| 52 Week High | $48.76 | $9.25 |
| Indicator | CDRE | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments - the Product segment, which is comprised of components that manufacture and sell products, and the Distribution segment, which is comprised of business that serves as a one-stop shop for law enforcement agencies that sells goods produced by the Product segment, as well as other third-party products.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.